Company intelligence / Profile preview

NatImmune

Copenhagen, N/A, Denmarkbiospace.com ↗

Ownership: Private
Development stage: Phase 1

Overview

NatImmune A/S was a Danish biotech company focused on developing therapeutic proteins for immune deficiencies. Its lead product, recombinant human Mannan-Binding Lectin (rhMBL), aimed to prevent severe infections in immunocompromised patients. The global rights to this product were licensed to Enzon Pharmaceuticals in 2005. Clinical development reached Phase Ib but was discontinued by Enzon in 2009 after failing to meet efficacy criteria. No further active programs are reported.

Therapeutic areas: Infectious Diseases
Modalities: Recombinant proteins (specifically recombinant human Mannan-Binding Lectin, rhMBL)
Industry: Biotech

Drug pipeline

1 asset

bLAC

Partnerships

ENZON Pharmaceuticals Inc. – exclusive worldwide rights partner for rhMBL outside Nordic countries

Beyond the preview

Go deeper on NatImmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NatImmune.

Explore the full profile